GlassScriptPhysician profile
Mojgan Redjamand
NPI 1538301718
$1,675.27
in general payments reported to CMS, 2019-2025
17 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $427 · 2023: $521 · 2024: $450 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $357.03 | 2022-2024 | Briviact |
| Janssen Pharmaceuticals, INC | $325.21 | 2021-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.26 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.63 | 2022-2024 | Jardiance, Stiolto Respimat |
| Xeris Pharmaceuticals, INC. | $73.23 | 2023-2024 | Gvoke Hypopen |
| Abbvie INC. | $71.20 | 2024-2025 | |
| Inari Medical, INC. | $58.59 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novartis Pharmaceuticals Corporation | $54.18 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $50.01 | 2024 | Terlivaz |
| Pfizer INC. | $38.77 | 2022-2023 | |
| Novo Nordisk INC | $34.17 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $24.34 | 2021 | |
| Merck Sharp & Dohme LLC | $20.53 | 2024 | Dificid |
| Bioxcel Therapeutics, INC. | $20.49 | 2023 | Igalmi |
| Melinta Therapeutics, LLC | $18.02 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.80 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.81 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mojgan Redjamand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.